Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Head & Neck 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Sarcoma 1Lymphoma 1Carcinoma 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
patritumab × Lymphoid × Clear all
NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
12 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡